Skip to content

Study · Systematic review · 2026

5 results

Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.

Pham TP, Vo TM, Nguyen TA, Dao TP, Ngo NP, Le TT, Tran TT, Pham TH, Huynh DM, Ha HA

Diabetes, obesity & metabolism10 Mar 2026Cited by 1 (Europe PMC)

PMID41804851 (opens in a new tab)DOI10.1111/dom.70635 (opens in a new tab)PepBankPUB-41804851
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes at high risk, semaglutide regimens showed the most consistent reduction in MACE versus placebo in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, semaglutide reduced serious heart and blood vessel events more consistently than placebo in a network meta-analysis.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse cardiovascular events (MACE)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide regimens showed the most consistent reduction in MACE and MI versus placebo, with the strongest effect observed for semaglutide combined with SGLT2 inhibition.
    1 context sentence
    Summary · context
    To compare the cardiovascular and renal effects of modern GLP-1RAs (dulaglutide, semaglutide, lixisenatide), tirzepatide and cotadutide in high-risk T2D populations, and to explore multivariate relationships among clinical outcomes.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes at high risk, semaglutide regimens showed the most consistent reduction in myocardial infarction versus placebo in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, semaglutide reduced heart attacks more consistently than placebo in a network meta-analysis.

    Peptide
    Semaglutide
    Outcome
    DecreaseMyocardial infarction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide regimens showed the most consistent reduction in MACE and MI versus placebo, with the strongest effect observed for semaglutide combined with SGLT2 inhibition.
    1 context sentence
    Summary · context
    To compare the cardiovascular and renal effects of modern GLP-1RAs (dulaglutide, semaglutide, lixisenatide), tirzepatide and cotadutide in high-risk T2D populations, and to explore multivariate relationships among clinical outcomes.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide 15 mg significantly reduced stroke risk in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered the risk of stroke in a network meta-analysis.

    Peptide
    Tirzepatide
    Outcome
    DecreaseStroke risk
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    15 mgAs given in this study (human).

    Source sentences

    Summary
    Dulaglutide 1.5 mg and tirzepatide 15 mg significantly reduced stroke risk.
    1 context sentence
    Summary · context
    To compare the cardiovascular and renal effects of modern GLP-1RAs (dulaglutide, semaglutide, lixisenatide), tirzepatide and cotadutide in high-risk T2D populations, and to explore multivariate relationships among clinical outcomes.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide 1 mg was among the regimens with marked reductions in UACR in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, semaglutide 1 mg was among the treatments that clearly lowered kidney protein leakage.

    Peptide
    Semaglutide
    Outcome
    DecreaseUrinary albumin-to-creatinine ratio (UACR)
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1 mgAs given in this study (human).

    Source sentences

    Summary
    Renal effects differed by endpoint: eGFR changes were generally modest, whereas UACR showed marked reductions, particularly with dulaglutide plus dapagliflozin, DPP-4 inhibitors and semaglutide 1 mg.
    1 context sentence
    Summary · context
    To compare the cardiovascular and renal effects of modern GLP-1RAs (dulaglutide, semaglutide, lixisenatide), tirzepatide and cotadutide in high-risk T2D populations, and to explore multivariate relationships among clinical outcomes.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide combined with an SGLT2 inhibitor showed the strongest reduction in MACE and myocardial infarction among the regimens compared.

    In plain wordsIn adults with type 2 diabetes, semaglutide taken with an SGLT2 inhibitor showed the strongest reduction in heart events, but this is a two-drug result.

    Peptide
    Semaglutide
    Outcome
    DecreaseMACE and myocardial infarction with semaglutide plus SGLT2 inhibition
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    with the strongest effect observed for semaglutide combined with SGLT2 inhibition.
    1 context sentence
    Summary · context
    To compare the cardiovascular and renal effects of modern GLP-1RAs (dulaglutide, semaglutide, lixisenatide), tirzepatide and cotadutide in high-risk T2D populations, and to explore multivariate relationships among clinical outcomes.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    11 Oct 2026, 00:04 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.